 |
Pharmacyclics Inc. Receives Issue Notice of Significant Bruton's Tyrosine Kinase (BTK) Patent
Dec 19, 2011
|
10.1 KB |
|
| |
SUNNYVALE, Calif., Dec. 19, 2011 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of cancer and immune mediated diseases, announced today issue notification from the United States Patent & Trademark Office (USPTO, www.uspto.gov...
|
|
Pharmacyclics® Announces Updated Results for BTK Inhibitor PCI-32765 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma at American Society for Hematology (ASH) Annual Meeting
Dec 13, 2011
|
13.2 KB |
|
| |
SAN DIEGO, Dec. 13, 2011 /PRNewswire/ -- Pharmacyclics, Inc (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of cancer and immune mediated diseases, announced today updated results of a Phase Ib/II trial of the selective, irreversible Bruton's tyrosine kinase (BT...
|
|
Pharmacyclics® Reports Interim Phase II Trial Results for BTK Inhibitor PCI-32765 in Mantle Cell Lymphoma at American Society of Hematology (ASH) Annual Meeting
Dec 12, 2011
|
13.4 KB |
|
| |
SAN DIEGO, Dec. 12, 2011 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of cancer and immune mediated diseases, announced today interim results from an ongoing Phase II trial of the selective irreversible Bruton's tyrosine ki...
|
|
Pharmacyclics Forms Pact to Develop and Commercialize PCI-32765 for Hematologic Cancers with Janssen Biotech, Inc.
Dec 8, 2011
|
12.3 KB |
|
| |
SUNNYVALE, Calif., Dec. 8, 2011 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), announced today that it has entered into a worldwide collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ), to develop and commercialize PCI-32765, a novel, oral, first-in-class Bruton's tyrosine kinas...
|
|
Pharmacyclics Appoints Chief Medical Officer Dr. Lori Anne Kunkel
Dec 2, 2011
|
8.8 KB |
|
| |
SUNNYVALE, Calif., Dec. 2, 2011 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced the appointment of Dr. Lori Anne Kunkel as its Chief Medical Officer. Dr. Kunkel is board certified in hematology, oncology and internal medicine and will provide strategic input and oversight into the company's clinical development programs and med...
|
|
Pharmacyclics Reports Fiscal 2012 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 53rd American Society of Hematology Annual Meeting
Nov 7, 2011
|
24.1 KB |
|
| |
SUNNYVALE, Calif., Nov. 7, 2011 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today reported financial results and recent developments for its fiscal first quarter ended September 30, 2011.
Financial Results for First Quarter Ended September 30, 2011
The non-GAAP (Generally Accepted Accounting Principles) net loss reported for the fisca...
|
|
Pharmacyclics Reports Financial Results and Recent Developments for Fiscal Year and Fourth Quarter 2011 - Conference Call Set for Today at 4:30 PM EDT
Sep 12, 2011
|
29.3 KB |
|
| |
SUNNYVALE, Calif., Sept. 12, 2011 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today reported financial results and recent developments for its fiscal year and fourth quarter ended June 30, 2011.
Financial Results for Year and Fourth Quarter Ended June 30, 2011
The non-GAAP (Generally Accepted Accounting Principles) net loss reported f...
|
|
Pharmacyclics Announces Date of Fiscal Year End 2011 Financial Results and Conference Call
Sep 8, 2011
|
8.4 KB |
|
| |
SUNNYVALE, Calif., Sept. 8, 2011 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of cancer and immune mediated diseases, today announced that it will report financial results for the fourth fiscal quarter and fiscal year ended...
|
|
Pharmacyclics Announces Collaboration with the National Cancer Institute to Develop its Novel Btk Inhibitor, PCI-32765 in Hematologic Malignancies
Aug 9, 2011
|
11.2 KB |
|
| |
SUNNYVALE, Calif., Aug. 9, 2011 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced the signing of a five-year Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to collaborate on the development of PCI-32765, a first-in-class, small molecule inhibitor of Bruton's tyrosine kinase (Btk) for...
|
|
Pharmacyclics Announces Results of Registered Direct Offering
Jun 17, 2011
|
9.9 KB |
|
| |
SUNNYVALE, Calif., June 17, 2011 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that it has entered into stock purchase agreements with various institutional investors and its CEO for the sale of 6,448,829 shares of its common stock in a registered direct offering at $8.85 per share, the closing price on June 16, 2011. Gross pr...
|
|
Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
Jun 6, 2011
|
20.3 KB |
|
| |
SUNNYVALE, Calif., June 6, 2011 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced data from the oral presentation of the Phase IB/II study of the Btk inhibitor, PCI-32765, in chronic lymphocytic leukemia / small cell lymphocytic lymphoma (CLL/SLL) at the 2011 American Society of Clinical Oncology Annual Meeting. The company will al...
|
|
Pharmacyclics Announces Oral Presentations and Clinical Update at Upcoming Medical Meetings
May 18, 2011
|
10.3 KB |
|
| |
SUNNYVALE, Calif., May 18, 2011 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that a clinical abstract on our Btk inhibitor, PCI-32765, has been selected for an oral presentation at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 3-7, 2011 in Chicago, IL. Additionally, two clinical abstracts on...
|
|
Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Third Quarter 2011
May 4, 2011
|
28.2 KB |
|
| |
SUNNYVALE, Calif., May 4, 2011 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today reported recent developments and financial results for its fiscal third quarter that ended March 31, 2011.
Recent Developments & Highlights
Broad Clinical Development Progress for Btk Inhibitor PCI-32765 in B-cell Malignancies
Based upon encouraging dat...
|
|
Pharmacyclics to Announce Third Quarter Fiscal 2011 Results and Host a Conference Call on May 4, 2011
Apr 29, 2011
|
8.5 KB |
|
| |
SUNNYVALE, Calif., April 29, 2011 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC), a clinical stage biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of cancer and immune mediated diseases, today announced that senior management will host a conference call and live audio webcast...
|
|
Pharmacyclics Achieves $7 Million Development Milestone for HDAC Inhibitor, PCI-24781 / S 78454 with Servier
Apr 26, 2011
|
11.3 KB |
|
| |
SUNNYVALE, Calif., April 26, 2011 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today that it has received a $7 million milestone payment for its histone deacetylase (HDAC) inhibitor, PCI-24781 / S 78454 from Les Laboratoires Servier ("Servier") based on an ex-US collaboration agreement signed in April of 2009. Over the past two yea...
|
|
Update on Preclinical Finding and Development Timeline for PCI-45292
Mar 2, 2011
|
10.2 KB |
|
| |
SUNNYVALE, Calif., March 2, 2011 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that further advancement of PCI-45292, a Btk inhibitor with exceptionally potent anti-arthritis activity in mice and rats, has been suspended following results from the current set of preclinical toxicology studies. The company hopes to have a new c...
|
|
Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011
Feb 4, 2011
|
24.5 KB |
|
| |
SUNNYVALE, Calif., Feb. 4, 2011 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today reported recent developments and financial results for its fiscal second quarter that ended December 31, 2010.
Recent Developments & Highlights
Broad Clinical Development Progress for Btk Inhibitor PCI-32765 in B-cell malignancies
Pharmacyclics has des...
|
|
Pharmacyclics to Announce Second Quarter Fiscal 2011 Results and Host a Conference Call on February 4, 2011
Feb 1, 2011
|
8.5 KB |
|
| |
SUNNYVALE, Calif., Feb. 1, 2011 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of cancer and immune mediated diseases, today announced that senior management will host a conference call and live audio webcast on Friday, Febru...
|
| |
Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human BTK-Inhibitor PCI-32765
Dec 7, 2010
|
57.6 KB |
|
| |
Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765
Dec 5, 2010
|
83.7 KB |
|
|
|
